Archives of Neuroscience

Published by: Kowsar

Intrathecal Mesenchymal Stem Cell Therapy in Multiple Sclerosis: A Follow-Up Study for Five Years After Injection

Mohammad Ali Sahraian 1 , 2 , * , Mandana Mohyeddin Bonab 3 , Sanaz Ahmadi Karvigh 1 , Sepideh Yazdanbakhsh 4 , Behrouz Nikbin 3 and Jamshid Lotfi 4
Authors Information
1 MS Research Center, Neuroscience Institute, Tehran University of Medical Sciences, Tehran, IR Iran
2 Department of Neurology, Sina Hospital, Tehran University of Medical Sciences, Tehran, IR Iran
3 Department of Immunology, Tehran University of Medical Sciences, Tehran, IR Iran
4 Iranian MS Society, Tehran, IR Iran
Article information
  • Archives of Neuroscience: July 01, 2014, 1 (2); 71-75
  • Published Online: July 1, 2014
  • Article Type: Research Article
  • Received: July 19, 2013
  • Revised: September 27, 2013
  • Accepted: September 28, 2013
  • DOI: 10.5812/archneurosci.13687

To Cite: Sahraian M A, Mohyeddin Bonab M, Ahmadi Karvigh S, Yazdanbakhsh S, Nikbin B, et al. Intrathecal Mesenchymal Stem Cell Therapy in Multiple Sclerosis: A Follow-Up Study for Five Years After Injection, Arch Neurosci. 2014 ; 1(2):71-75. doi: 10.5812/archneurosci.13687.

Abstract
Copyright © 2014, Tehran University of Medical Sciences. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Patients and Methods
4. Results
5. Discussion
Acknowledgements
Footnotes
References
  • 1. Kantarci OH. Genetics and natural history of multiple sclerosis. Semin Neurol. 2008; 28(1): 7-16[DOI][PubMed]
  • 2. Kremenchutzky M, Rice GP, Baskerville J, Wingerchuk DM, Ebers GC. The natural history of multiple sclerosis: a geographically based study 9: observations on the progressive phase of the disease. Brain. 2006; 129: 584-94[DOI][PubMed]
  • 3. Petratos S, Azari MF, Ozturk E, Papadopoulos R, Bernard CC. Novel therapeutic targets for axonal degeneration in multiple sclerosis. J Neuropathol Exp Neurol. 2010; 69(4): 323-34[DOI][PubMed]
  • 4. Martino G, Franklin RJ, Baron Van Evercooren A, Kerr DA. Stem cell transplantation in multiple sclerosis: current status and future prospects. Nat Rev Neurol. 2010; 6(5): 247-55[DOI][PubMed]
  • 5. Crigler L, Robey RC, Asawachaicharn A, Gaupp D, Phinney DG. Human mesenchymal stem cell subpopulations express a variety of neuro-regulatory molecules and promote neuronal cell survival and neuritogenesis. Exp Neurol. 2006; 198(1): 54-64[DOI][PubMed]
  • 6. Siatskas C, Payne NL, Short MA, Bernard CC. A consensus statement addressing mesenchymal stem cell transplantation for multiple sclerosis: it's time! Stem Cell Rev. 2010; 6(4): 500-6[DOI][PubMed]
  • 7. Tirotta E, Carbajal KS, Schaumburg CS, Whitman L, Lane TE. Cell replacement therapies to promote remyelination in a viral model of demyelination. J Neuroimmunol. 2010; 224(1-2): 101-7[DOI][PubMed]
  • 8. Pittenger MF, Mackay AM, Beck SC, Jaiswal RK, Douglas R, Mosca JD, et al. Multilineage potential of adult human mesenchymal stem cells. Science. 1999; 284(5411): 143-7[PubMed]
  • 9. Yang J, Rostami A, Zhang GX. Cellular remyelinating therapy in multiple sclerosis. J Neurol Sci. 2009; 276(1-2): 1-5[DOI][PubMed]
  • 10. Bai L, Lennon DP, Eaton V, Maier K, Caplan AI, Miller SD, et al. Human bone marrow-derived mesenchymal stem cells induce Th2-polarized immune response and promote endogenous repair in animal models of multiple sclerosis. Glia. 2009; 57(11): 1192-203[DOI][PubMed]
  • 11. Gordon D, Pavlovska G, Glover CP, Uney JB, Wraith D, Scolding NJ. Human mesenchymal stem cells abrogate experimental allergic encephalomyelitis after intraperitoneal injection, and with sparse CNS infiltration. Neurosci Lett. 2008; 448(1): 71-3[DOI][PubMed]
  • 12. Kassis I, Grigoriadis N, Gowda-Kurkalli B, Mizrachi-Kol R, Ben-Hur T, Slavin S, et al. Neuroprotection and immunomodulation with mesenchymal stem cells in chronic experimental autoimmune encephalomyelitis. Arch Neurol. 2008; 65(6): 753-61[DOI][PubMed]
  • 13. Zappia E, Casazza S, Pedemonte E, Benvenuto F, Bonanni I, Gerdoni E, et al. Mesenchymal stem cells ameliorate experimental autoimmune encephalomyelitis inducing T-cell anergy. Blood. 2005; 106(5): 1755-61[DOI][PubMed]
  • 14. Zhang J, Li Y, Chen J, Cui Y, Lu M, Elias SB, et al. Human bone marrow stromal cell treatment improves neurological functional recovery in EAE mice. Exp Neurol. 2005; 195(1): 16-26[DOI][PubMed]
  • 15. Karussis D, Karageorgiou C, Vaknin-Dembinsky A, Gowda-Kurkalli B, Gomori JM, Kassis I, et al. Safety and immunological effects of mesenchymal stem cell transplantation in patients with multiple sclerosis and amyotrophic lateral sclerosis. Arch Neurol. 2010; 67(10): 1187-94[DOI][PubMed]
  • 16. Mohyeddin Bonab M, Yazdanbakhsh S, Lotfi J, Alimoghaddom K, Talebian F, Hooshmand F, et al. Does mesenchymal stem cell therapy help multiple sclerosis patients? Report of a pilot study. Iran J Immunol. 2007; 4(1): 50-7[PubMed]
  • 17. Yamout B, Hourani R, Salti H, Barada W, El-Hajj T, Al-Kutoubi A, et al. Bone marrow mesenchymal stem cell transplantation in patients with multiple sclerosis: a pilot study. J Neuroimmunol. 2010; 227(1-2): 185-9[DOI][PubMed]
  • 18. Freedman MS, Bar-Or A, Atkins HL, Karussis D, Frassoni F, Lazarus H, et al. The therapeutic potential of mesenchymal stem cell transplantation as a treatment for multiple sclerosis: consensus report of the International MSCT Study Group. Mult Scler. 2010; 16(4): 503-10[DOI][PubMed]
  • 19. Marmont AM. New horizons in the treatment of autoimmune diseases: immunoablation and stem cell transplantation. Annu Rev Med. 2000; 51: 115-34[DOI][PubMed]
  • 20. Beyth S, Borovsky Z, Mevorach D, Liebergall M, Gazit Z, Aslan H, et al. Human mesenchymal stem cells alter antigen-presenting cell maturation and induce T-cell unresponsiveness. Blood. 2005; 105(5): 2214-9[DOI][PubMed]
  • 21. Lassmann H. Stem cell and progenitor cell transplantation in multiple sclerosis: the discrepancy between neurobiological attraction and clinical feasibility. J Neurol Sci. 2005; 233(1-2): 83-6[DOI][PubMed]
  • 22. Le Blanc K, Tammik C, Rosendahl K, Zetterberg E, Ringden O. HLA expression and immunologic properties of differentiated and undifferentiated mesenchymal stem cells. Exp Hematol. 2003; 31(10): 890-6[PubMed]
  • 23. Gregory CA, Prockop DJ, Spees JL. Non-hematopoietic bone marrow stem cells: molecular control of expansion and differentiation. Exp Cell Res. 2005; 306(2): 330-5[DOI][PubMed]
  • 24. Krampera M, Pasini A, Pizzolo G, Cosmi L, Romagnani S, Annunziato F. Regenerative and immunomodulatory potential of mesenchymal stem cells. Curr Opin Pharmacol. 2006; 6(4): 435-41[DOI][PubMed]
  • 25. Caplan AI, Dennis JE. Mesenchymal stem cells as trophic mediators. J Cell Biochem. 2006; 98(5): 1076-84[DOI][PubMed]
  • 26. Uccelli A, Mancardi G. Stem cell transplantation in multiple sclerosis. Curr Opin Neurol. 2010; 23(3): 218-25[DOI][PubMed]
  • 27. Garzon-Muvdi T, Quinones-Hinojosa A. Neural stem cell niches and homing: recruitment and integration into functional tissues. ILAR J. 2009; 51(1): 3-23[PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiation Alert
via Google Reader

Readers' Comments